EMEA-001860-PIP03-16-M07
Key facts
| Invented name |
Emgality
|
| Active substance |
Galcanezumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0142/2022
|
| PIP number |
EMEA-001860-PIP03-16-M07
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of migraine headaches
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|